TENAX THERAPEUTICS, INC. 10-Q

ITEM 1A. RISK FACTORS The risks we face have not materially changed from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022. 28 Table of Contents ITEM 6. EXHIBITS The following exhibits are being filed or furnished as part of this Quarterly Report on Form 10-Q and are numbered in accordance with Item 601 of Regulation S-K: Exhibit Number Description 3.1 Fourth Amended and Restated Bylaws of Tenax Therapeutics, Inc. (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on August 15, 2023). 31.1* Certification of President and Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002. 31.2* Certification of Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002. 32.1** Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2** Certification of Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101* Inline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q. 104* Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. * Filed herewith ** Furnished herewith 29 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 13, 2023 TENAX THERAPEUTICS, INC. By: Eliot M. Lurier Eliot M. Lurier Interim Chief Financial Officer (On behalf of the Registrant and as Principal Financial and Accounting Officer) 30